|Articles|August 28, 2021

2 Reported Deaths After Second Doses of Suspended Moderna Vaccine Supply

The deaths occurred this month in Japan, and investigations into the deaths and the vaccine batches are ongoing.

Japan has reported that 2 men have died after taking their second doses of the Moderna COVID-19 vaccine supply that were later suspended. Both men died in August shortly after their second doses, according to Japan's Health Ministry.

"At this time, we do not have any evidence that these deaths are caused by the Moderna COVID-19 vaccine," Moderna and Takeda said in a statement that was reported by Reuters. "It is important to conduct a formal investigation to determine whether there is any connection."

On Thursday, the country announced it had halted the use of 1.63 million doses over claims tiny particles were found in unused vials. The suspension of the 3 lots of vaccines was a precaution.

The vaccine batches were produced by Rovi, a pharmaceutical company in Spain. The company was made aware of the particulate matter, and it is working with officials to address the matter.

“The detection of this particulate matter refers to certain vials of one product lot distributed exclusively in Japan. ROVI, as well as Moderna and Takeda, the company distributing the referred vaccine in Japan, are working with health authorities in order to clarify and solve, if applicable, this incident,” the company statement read. “The origin of this manufacturing incident may be in one of ROVI’s manufacturing lines. ROVI is working in order to provide with all the information and assistance that may be needed to progress with the investigation. As a precaution, this lot and two adjacent lots have been put on hold.”


Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
FAQ: XDR Shigella
Here is some important information around this pathogen and the intestinal infection.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.